---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000149"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T08:51:21.246471+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance

## Summary
- Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.
- GAAP diluted EPS $0.55 (+162%); Non-GAAP diluted EPS $0.91 (+98%).
- Raised full-year 2024 guidance for total revenue, Non-GAAP operating margin, and Non-GAAP EPS.
- Retired $495M convertible debt in cash, eliminating ~4M dilutive shares.
- Over 3,800 children on VOXZOGO; majority of US new starts under age 5.

## SEC filing metadata
- accession: 0001048477-24-000149
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/0001048477-24-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/bmrn-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000149
- JSON: https://secwatch.observer/filing/0001048477-24-000149.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.